Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $82.1667.Several equities analysts have commented on TECX shares. Wells Fargo & Company assumed coverage on shares of Tectonic Therapeutic in a report on Monday, October 20th. They issued an "overweight" rating and a $101.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Tectonic Therapeutic in a research note on Wednesday, October 8th. Finally, Oppenheimer assumed coverage on shares of Tectonic Therapeutic in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $80.00 price objective for the company.Get Tectonic Therapeutic alerts:Check Out Our Latest Research Report on TECXInstitutional Trading of Tectonic TherapeuticSeveral large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd raised its stake in Tectonic Therapeutic by 451.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company's stock worth $62,000 after acquiring an additional 3,247 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Tectonic Therapeutic by 218.0% during the 3rd quarter. Millennium Management LLC now owns 238,170 shares of the company's stock valued at $3,737,000 after purchasing an additional 163,281 shares during the last quarter. Jain Global LLC acquired a new position in Tectonic Therapeutic during the 3rd quarter worth approximately $1,122,000. First Light Asset Management LLC bought a new position in Tectonic Therapeutic in the 3rd quarter valued at approximately $3,176,000. Finally, Citadel Advisors LLC lifted its stake in Tectonic Therapeutic by 80.8% in the 3rd quarter. Citadel Advisors LLC now owns 298,388 shares of the company's stock valued at $4,682,000 after purchasing an additional 133,342 shares during the last quarter. 62.63% of the stock is owned by institutional investors and hedge funds. Tectonic Therapeutic Price PerformanceShares of NASDAQ:TECX opened at $21.47 on Friday. The business's 50 day simple moving average is $17.55 and its 200 day simple moving average is $20.11. Tectonic Therapeutic has a 1 year low of $13.70 and a 1 year high of $61.07. The company has a market capitalization of $401.82 million, a P/E ratio of -5.56 and a beta of 3.23. Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.03. On average, sell-side analysts anticipate that Tectonic Therapeutic will post -8.31 EPS for the current fiscal year. About Tectonic Therapeutic (Get Free Report)Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. Further ReadingFive stocks we like better than Tectonic TherapeuticWhere Do I Find 52-Week Highs and Lows?Meta Platforms May Ditch NVIDIA Chips—Here’s Why Investors CareHow to Start Investing in Real EstateSoFi Technologies: From Fintech Speculation to Profit EngineWith Risk Tolerance, One Size Does Not Fit AllGold to $5,000? What Bank of America and UBS Have to SayThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Tectonic Therapeutic Right Now?Before you consider Tectonic Therapeutic, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tectonic Therapeutic wasn't on the list.While Tectonic Therapeutic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here